StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Merck (MRK), Eisai Co. Granted FDA Breakthrough Therapy Designation for LENVIMA
July 31, 2018 5:46 AM
Eisai Co., Ltd. and Merck & Co., Inc. Kenilworth, N.J., U.S.A. (NYSE: MRK), known as MSD outside the United States ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
FDA
Management Comments
Next Articles
Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. Announce U.S. FDA Grants Breakthrough Therapy Designation for LENVIMA
July 30, 2018 11:01 PM
Merck (MRK) Reports Positive Opinion from EMA for KEYTRUDA (pembrolizumab) Combination with Pemetrexed & Platinum Chemotherapy
July 30, 2018 6:47 AM
Merck profit beats, but Keytruda sales fail to impress
July 27, 2018 6:57 AM
Merck (MRK) Tops Q2 EPS by 3c, Updates FY Guidance
July 27, 2018 6:46 AM